Navigation Links
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
Date:12/8/2008

tory of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995; 333:1253-1258. (8) Wang H, Chuhjo T, Yasue S, Omine M, Naka S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100 (12):3897-3902. (9) Iwanga M, Furukawa K, Amenomori T, et al. Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol. 1998;102 (2):465-474. (10) Maciejewski JP, Risitano AM, Sloand EM, et al. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol. 2001;115:1015-1022. (11) Hill A, Richards S, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137 (3):181-192. Poster: III-520
'/>"/>
SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
2. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
6. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
7. GEN Reports on the Trend Toward Predictive Toxicogenomics
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ZIONA, Israel , August 3, 2015 ... BVXV) today announced it received the statistical analysis of results ... (M-001), administered in the BVX-005 phase II trial which took ... strains which did not exist at the time of the ... strain that caused the epidemic in the United ...
(Date:8/3/2015)... 3, 2015  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... an exclusive licensing agreement to develop and commercialize multiple ... Limited, a holding company for premier antibody development and ... Under the terms of the agreement, Sorrento ... for the North American, European and Japanese market. Each ...
(Date:7/31/2015)... 31, 2015  Physicians and payers alone do ... market. Patients are better informed and getting increasingly ... therapies. This shift in power is reshaping the ... patient-focused marketing. As part of this ... it,s important to educate, communicate and engage patients ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... solutions for drugs, biologics and consumer health products, today welcomed the announcement by ... OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today ... management solution, as well as announced the date of its next major release. ... of contract management tasks as well as enhancements to the customer experience. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... of it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive ... leaders from healthcare organizations with access to the tactics, techniques and practices required ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article ... Stem Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" ... to the report, the new study showed that harvesting stem cell-rich bone marrow from ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... firm, announced today that Joe Williams has joined its growing California employee benefits ... HUB's differentiated service model to his clients. Mr. Williams will be joining the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... too many clinicians still using unproven treatments , , ... and teens, individual and group cognitive behavioral therapy ... and other trauma symptoms, say U.S. researchers who ... subject. , However, despite the proven effectiveness of ...
... a criminal plea and pay $425 million to resolve ... by the Food and Drug,Administration (FDA), the Justice Department ... Cephalon employees and filed under,the qui tam provisions of ... in a scheme to market Gabitril, Actiq and Provigil ...
... Food Prices on the Rise New Tools to Help Make ... finance expert Suze Orman,is the latest celebrity to join the ... their health. With rising food costs, many,families are economizing on ... nutrition. At about 25 cents per 8 ounce glass, on ...
... In a letter to Dr. Mary S. ... ) board,s Governance Committee, the,CtW Investment Group questions ... Walgreens and challenges the arguments put forward by ... of Longs. Citing analysis prepared by expert anti-trust ...
... Pa., Sept. 29 Herley Industries,Inc. (Nasdaq: ... England division in,Woburn, Massachusetts, has a contract totaling ... NY, for the manufacture of,complex switch filter assemblies ... ("ESM") system., The MH-60R Multi-Mission Helicopter (MMH) ...
... LegalView recently informed mesothelioma blog readers of improper removal of asbestos ... risk for developing mesothelioma cancer. The city used an unapproved "wet ... asbestos dust once the water evaporates. , ... Denver, ...
Cached Medicine News:Health News:Cognitive Behavioral Therapy Best for Traumatized Youths 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 2Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 3Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 4Health News:Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing 5Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 2Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 3Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 2Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 3Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 4Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 5Health News:CtW Investment Group Challenges Longs' Anti-Trust Arguments (NYSE: LDG) 6Health News:Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter 2Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 2Health News:LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition 3
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
... The proprietary Ambient Noise Reduction ... out anaverage of 75% of distracting ... acoustic canceling effect is different from ... out some portions of body sounds ...
... Afinion AS100 Analyzer ... on-the-spot testing, regardless of ... test was launched in ... CRP test in May ...
... Virion\Serions comprehensive line of ELISA Classic serology ... viral, and fungal pathogens with rapid, standardized ... IgA antibodies. All of the ELISA antigens ... in their own laboratories under the control ...
Medicine Products: